{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:22:45Z","timestamp":1790882565077,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81470359"],"award-info":[{"award-number":["81470359"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.humpath.2018.08.025","type":"journal-article","created":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T01:47:54Z","timestamp":1536803274000},"page":"166-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK\/T-cell lymphoma, nasal type, is associated with disease progression and prognosis"],"prefix":"10.1016","volume":"83","author":[{"given":"Jumei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Nong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2018.08.025_bb0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.beha.2013.04.006","article-title":"Molecular underpinning of extranodal NK\/T-cell lymphoma","volume":"26","author":"Huang","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.humpath.2018.08.025_bb0010","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1182\/blood-2013-01-453233","article-title":"How I treat NK\/T-cell lymphomas","volume":"121","author":"Tse","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2018.08.025_bb0015","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2009.3","article-title":"Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer\u2013cell malignancies","volume":"23","author":"Iqbal","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2018.08.025_bb0020","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/435423","article-title":"The genetic deletion of 6q21 and PRDM1 and clinical implications in extranodal NK\/T cell lymphoma, nasal type","volume":"2015","author":"Liang","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.humpath.2018.08.025_bb0025","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2009-05-221275","article-title":"Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK\/T-cell lymphoma, nasal type","volume":"115","author":"Huang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2018.08.025_bb0030","doi-asserted-by":"crossref","first-page":"6857","DOI":"10.1128\/MCB.25.16.6857-6868.2005","article-title":"Subunit contributions to histone methyltransferase activities of fly and worm polycomb group complexes","volume":"25","author":"Ketel","year":"2005","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.humpath.2018.08.025_bb0035","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2174\/1389203716666150409100233","article-title":"Targeting EZH2 for cancer therapy: progress and perspective","volume":"16","author":"Han Li","year":"2015","journal-title":"Curr Protein Pept Sci"},{"key":"10.1016\/j.humpath.2018.08.025_bb0040","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.humpath.2014.07.002","article-title":"Diffuse large B-cell lymphoma with histone H3 trimethylation at lysine 27: another poor prognostic phenotype independent of c-Myc\/Bcl2 coexpression","volume":"45","author":"Oh","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.humpath.2018.08.025_bb0045","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.2005.01.5180","article-title":"EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast","volume":"24","author":"Bachmann","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2018.08.025_bb0050","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1751-2980.2010.00420.x","article-title":"Expression of polycomb protein EZH2 in multi-stage tissues of gastric carcinogenesis","volume":"11","author":"Cai","year":"2010","journal-title":"J Dig Dis"},{"key":"10.1016\/j.humpath.2018.08.025_bb0055","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1182\/blood-2009-03-213496","article-title":"Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells","volume":"114","author":"Fiskus","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2018.08.025_bb0060","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1182\/blood-2012-08-450494","article-title":"EZH2 overexpression in natural killer\/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity","volume":"121","author":"Yan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2018.08.025_bb0065","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","article-title":"Extranodal nk\/T-cell lymphoma, nasal type","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.humpath.2018.08.025_bb0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1756-9966-33-7","article-title":"The downregulation of PRDM1\/Blimp-1 is associated with aberrant expression of miR-223 in extranodal NK\/T-cell lymphoma, nasal type","volume":"33","author":"Liang","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.humpath.2018.08.025_bb0075","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1002\/hon.2362","article-title":"Hypermethylation of PRDM1\/Blimp-1 promoter in extranodal NK\/T-cell lymphoma, nasal type: an evidence of predominant role in its downregulation","volume":"35","author":"Zhang","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.humpath.2018.08.025_bb0080","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41419-017-0260-8","article-title":"Neuroglobin boosts axon regeneration during ischemic reperfusion via p38 binding and activation depending on oxygen signal","volume":"9","author":"Xiong","year":"2018","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.humpath.2018.08.025_bb0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-016-0561-z","article-title":"STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer","volume":"15","author":"Pan","year":"2016","journal-title":"Mol Cancer"},{"key":"10.1016\/j.humpath.2018.08.025_bb0090","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.bbadis.2018.03.002","article-title":"PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras\/Erk\/EMT activation","volume":"1864","author":"Qiu","year":"2018","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.humpath.2018.08.025_bb0095","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1158\/1078-0432.CCR-14-1216","article-title":"Global promoter methylation analysis reveals novel candidate tumor suppressor genes in natural killer cell lymphoma","volume":"21","author":"Kucuk","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2018.08.025_bb0100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ajpath.2012.09.012","article-title":"HACE1 is a tumor suppressor gene candidate in natural killer cell neoplasms","volume":"182","author":"Kucuk","year":"2013","journal-title":"Am J Pathol"},{"key":"10.1016\/j.humpath.2018.08.025_bb0105","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/leu.2009.91","article-title":"STAT3 transcription factor is constitutively activated and is oncogenic in nasal-type NK\/T-cell lymphoma","volume":"23","author":"Coppo","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2018.08.025_bb0110","doi-asserted-by":"crossref","first-page":"17764","DOI":"10.18632\/oncotarget.3776","article-title":"Genetic alterations of JAK\/STAT cascade and histone modification in extranodal NK\/T-cell lymphoma nasal type","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2018.08.025_bb0115","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2016-01-690701","article-title":"EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer\/T-cell lymphoma","volume":"128","author":"Yan","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2018.08.025_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021583","article-title":"Determinants of sensitivity to DZNep induced apoptosis in multiple myeloma cells","volume":"6","author":"Xie","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.humpath.2018.08.025_bb0125","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3892\/or.2013.2922","article-title":"Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells","volume":"31","author":"Nakagawa","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.humpath.2018.08.025_bb0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12185-016-2124-x","article-title":"Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies","volume":"105","author":"Sashida","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.humpath.2018.08.025_bb0135","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc.2016.83","article-title":"Maintaining cell identity: PRC2-mediated regulation of transcription and cancer","volume":"16","author":"Comet","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.humpath.2018.08.025_bb0140","doi-asserted-by":"crossref","first-page":"8570","DOI":"10.1158\/1078-0432.CCR-05-1047","article-title":"Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder","volume":"11","author":"Raman","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2018.08.025_bb0145","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bcmd.2014.07.013","article-title":"Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia","volume":"54","author":"Rabello Ddo","year":"2015","journal-title":"Blood Cells Mol Dis"},{"key":"10.1016\/j.humpath.2018.08.025_bb0150","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/mc.20413","article-title":"Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers","volume":"47","author":"Wei","year":"2008","journal-title":"Mol Carcinog"},{"key":"10.1016\/j.humpath.2018.08.025_bb0155","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.molonc.2012.06.002","article-title":"Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes","volume":"6","author":"Holm","year":"2012","journal-title":"Mol Oncol"},{"key":"10.1016\/j.humpath.2018.08.025_bb0160","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/1471-2407-12-470","article-title":"Expression and significance of histone H3K27 demethylases in renal cell carcinoma","volume":"12","author":"Shen","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.humpath.2018.08.025_bb0165","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3892\/ijo.2013.2062","article-title":"High expression of trimethylated histone H3 at lysine 27 predicts better prognosis in non\u2013small cell lung cancer","volume":"43","author":"Chen","year":"2013","journal-title":"Int J Oncol"},{"key":"10.1016\/j.humpath.2018.08.025_bb0170","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ccr.2013.04.008","article-title":"Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem\u2013like cells","volume":"23","author":"Kim","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2018.08.025_bb0175","doi-asserted-by":"crossref","first-page":"6025","DOI":"10.1038\/ncomms7025","article-title":"Activating mutations of STAT5B and STAT3 in lymphomas derived from gammadelta-T or NK cells","volume":"6","author":"Kucuk","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.humpath.2018.08.025_bb0180","doi-asserted-by":"crossref","first-page":"76793","DOI":"10.18632\/oncotarget.12529","article-title":"Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus\u2013associated T and natural killer cell lymphoma cells","volume":"7","author":"Ando","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.humpath.2018.08.025_bb0185","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4143\/crt.2014.46.3.209","article-title":"Regulation and role of EZH2 in cancer","volume":"46","author":"Yamaguchi","year":"2014","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.humpath.2018.08.025_bb0190","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/0006-291X(86)90048-3","article-title":"3-deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60","volume":"135","author":"Glazer","year":"1986","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.humpath.2018.08.025_bb0195","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1101\/gad.1524107","article-title":"Pharmacologic disruption of Polycomb-repressive complex 2\u2013mediated gene repression selectively induces apoptosis in cancer cells","volume":"21","author":"Tan","year":"2007","journal-title":"Genes Dev"},{"key":"10.1016\/j.humpath.2018.08.025_bb0200","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccr.2012.09.003","article-title":"Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-cell lymphomas","volume":"22","author":"Zhang","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2018.08.025_bb0205","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817718303514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817718303514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:34:55Z","timestamp":1758645295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817718303514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":41,"alternative-id":["S0046817718303514"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2018.08.025","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK\/T-cell lymphoma, nasal type, is associated with disease progression and prognosis","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2018.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}